FDA APPROVES FIRST TREATMENT FOR NONMETASTATIC, CASTRATION-RESISTANT PROSTATE CANCER

被引:0
|
作者
Aschenbrenner, Diane S.
机构
关键词
D O I
10.1097/01.NAJ.0000534848.12514.1c
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
引用
收藏
页码:26 / 26
页数:1
相关论文
共 50 条
  • [41] Castration-resistant Prostate cancer: Treatment is differentiated
    Wolff, Johannes M.
    AKTUELLE UROLOGIE, 2011, 42 (02)
  • [42] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [43] Sequencing Treatment for Castration-Resistant Prostate Cancer
    Handy, Catherine E.
    Antonarakis, Emmanuel S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
  • [44] Sequencing Treatment for Castration-Resistant Prostate Cancer
    Catherine E. Handy
    Emmanuel S. Antonarakis
    Current Treatment Options in Oncology, 2016, 17
  • [45] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [46] Optimal treatment for castration-resistant prostate cancer
    Izumi, Kouji
    Namiki, Mikio
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 498 - 498
  • [47] Darolutamide for treatment of castration-resistant prostate cancer
    Rhea, L. P.
    Mendez-Marti, S.
    Aragon-Ching, J. B.
    DRUGS OF TODAY, 2020, 56 (03) : 185 - 193
  • [50] ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris Y.
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)